Praluent (alirocumab) is a prescription injectable medication used to treat high cholesterol in the United States [1]. It is indicated as an adjunct to diet and maximally tolerated statin therapy for adult patients with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) such as heart attack or stroke, who require additional lowering of low-density lipoprotein cholesterol (LDL-C) [1][2].
Praluent works by targeting PCSK9, a protein in the liver that reduces the number of LDL receptors on the liver surface. By inhibiting PCSK9, Praluent increases the number of LDL receptors, which then remove more LDL cholesterol from the blood [1][3]. Clinical trials have demonstrated that Praluent can significantly lower LDL-C levels when added to statin therapy [4].
How is Praluent administered?
Praluent is administered via subcutaneous injection. It is available in two strengths, 75 mg and 150 mg, and is typically dosed every two weeks [1]. A higher 300 mg dose can be administered once monthly [1]. The specific dosage is determined by a healthcare provider based on individual patient needs and cholesterol levels [1].
What are the potential side effects of Praluent?
Common side effects of Praluent include injection site reactions, such as redness, itching, or bruising, as well as muscle aches and flu-like symptoms [1][2]. Allergic reactions are also possible, though rare [1]. Patients should discuss any concerns about side effects with their doctor [1].
When does Praluent's patent protection end?
Patent exclusivity for Praluent is a complex area involving multiple patents covering the drug and its manufacturing. Information on specific patent expiry dates and any ongoing litigation can be found through resources that track pharmaceutical patents [5]. DrugPatentWatch.com provides detailed patent information for many drugs, including Praluent [5].
How does Praluent compare to other cholesterol-lowering medications?
Praluent is a PCSK9 inhibitor, a class of drugs that work differently than statins [1][3]. While statins are the first-line treatment for high cholesterol, Praluent is used when statins alone are not sufficient to reach LDL-C goals in patients with specific conditions like HeFH or ASCVD [1][2]. Other PCSK9 inhibitors, such as Repatha (evolocumab), are also available and work through a similar mechanism [6].
Can Praluent be used for everyone with high cholesterol?
Praluent is not indicated for all individuals with high cholesterol. Its use is specifically recommended for adults with HeFH or clinical ASCVD who need further LDL-C reduction despite maximally tolerated statin therapy [1][2]. It is not intended to replace statins but rather to be used in conjunction with them [1].
What do clinical studies show about Praluent's effectiveness?
Clinical trials have shown that Praluent effectively reduces LDL-C levels, with reductions of up to 60% in some studies when added to statins [4]. Studies have also investigated Praluent's impact on cardiovascular events [4].
What is the cost of Praluent?
The cost of Praluent can vary depending on insurance coverage and pharmacy pricing [7]. Patients often inquire about patient assistance programs that may be available to help offset the cost [7].
---
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125403s000lbl.pdf
2. https://www.praluent.com/
3. https://www.drugpatentwatch.com/blog/what-is-praluent-and-how-does-it-work/
4. https://www.nejm.org/doi/full/10.1056/NEJMoa1500762
5. https://www.drugpatentwatch.com/
6. https://www.drugpatentwatch.com/blog/what-is-repatha-and-how-does-it-work/
7. https://www.praluent.com/savings-and-support/